Compare Citius Pharmaceuticals Inc (CTXR) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance

Citius Pharmaceuticals IncTrade

Schwab US Dividend Equity ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Schwab US Dividend Equity ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Schwab US Dividend Equity ETF trades at $34.18. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

	CTXR	SCHD
Market Cap	$20.01M	—
Sector	Health	Broad Market / Factor
52-Week High	$1.82	$34.27
52-Week Low	$0.48	$26.44
Enterprise Value	$16.23M	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

CTXR

Citius Oncology appoints Jonathan Peri as new independent board member to strengthen governance.PRNewsWire · 5 hours agoBullish View details →

SCHD

SCHD ETF's index reshuffle caused unexpected high taxable distributions in 2024, hitting taxable accounts hard.24/7 Wall Street · 19 hours agoNeutral Vanguard High Dividend Yield ETF lags S&P 500 by $141K over 10 years despite dividends.24/7 Wall Street · 1 day agoBearish WisdomTree U.S. Total Dividend ETF (DTD) rated 'hold' for balanced factors but overlaps 57% with S&P 500 ETFs.Seeking Alpha · 1 day agoNeutral View details →

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

About Schwab US Dividend Equity ETF

SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.